8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 27, 2026·SEC
Material company update
Mar 5, 2026·SEC
Compass Therapeutics, Inc.(CMPX)Earnings, Financials & Key Ratios
CMPX•NASDAQ
$2.32
Price updated Jul 7, 2026
AboutCompass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Show more
- Revenue$0-100.0%
- EBITDA-$71M-30.1%
- Net Income-$66M-34.7%
- EPS (Diluted)-0.42-16.7%
- ROE-41.29%-14.5%
CMPX Price & Volume
Compass Therapeutics, Inc. (CMPX) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Liquidity Buffer
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding dependency
Key Thesis Takeaways
- Compass Therapeutics operates as a pre-revenue biotechnology entity, with its valuation entirely contingent upon the successful advancement of its bispecific antibody pipeline.
- The company faces significant financial pressure, as evidenced by quarterly R&D expenditures frequently exceeding $13 million without any offsetting commercial revenue.
- Investors should monitor the company's ability to secure additional capital, as the current cash position of $30.6 million as of 2025Q4 appears insufficient to sustain long-term clinical trial operations.
Verdict Logic
the company's cash position of $30.6 million against quarterly operating losses often exceeding $15 million suggests a high risk of near-term shareholder dilution.
CMPX Growth Metrics
Compass Therapeutics, Inc. (CMPX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-23.45%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-5.93%
Return on Capital
10 Years-59.26%
5 Years-45.58%
3 Years-37.95%
Last Year-43.21%
CMPX Recent Earnings
Compass Therapeutics, Inc. (CMPX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.10+0.0%
$0.10
Rev
—
$818,182
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.09+10.0%
$0.10
Rev
—
$900,000
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.08+42.9%
$0.14
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.14-7.7%
$0.13
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.10vs $0.10+0.0% | —vs $818,182 |
| Q2 2026 | Mar 5, 2026 | $0.09vs $0.10+10.0% | —vs $900,000 |
| Q4 2025 | Nov 5, 2025 | $0.08vs $0.14+42.9% | — |
| Q3 2025 | Aug 11, 2025 | $0.14vs $0.13-7.7% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Compass Therapeutics, Inc. (CMPX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.32 | $320.82M | -5.52 | -100% | — | -41.29% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $3.50 | $145.75M | -1029.41 | 10.37% | 52.16% | — | — | |
| $3.38 | $241.82M | -2.40 | — | — | -30.9% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — |
Compare CMPX vs Peers
Compass Therapeutics, Inc. (CMPX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CMPX SEC Filings & Documents
Compass Therapeutics, Inc. (CMPX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CMPX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CMPX Frequently Asked Questions
Compass Therapeutics, Inc. (CMPX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
How fast is Compass Therapeutics, Inc. growing?
Compass Therapeutics, Inc. (CMPX) saw revenue decline by 100.0% over the past year.
Is CMPX profitable?
Compass Therapeutics, Inc. (CMPX) reported a net loss of $68.2M for fiscal year 2025.
Dividend & Returns
What is CMPX's return on equity?
Compass Therapeutics, Inc. (CMPX) has a return on equity (ROE) of -41.3%. Negative ROE indicates the company is unprofitable.
What is Compass Therapeutics, Inc.'s free cash flow?
Compass Therapeutics, Inc. (CMPX) had negative free cash flow of $53.3M in fiscal year 2025, likely due to heavy capital investments.